GSK.L GSK plc
P/E
13.559859
Forward P/E
10.007744
Price/Sales
2.3541424
Beta
0.294
Div Yield
0.0353%
Market Cap
--
Company Analysis
Latest News
GSK wins Canada approval for Exdensur, first twice-yearly respiratory biologic
Health Canada approved GSK’s Exdensur (depemokimab) for two distinct respiratory indications. The drug serves as an add-on maintenance treatment for severe...
GSK and Spero Win FDA Approval for Utebzi, First Oral Carbapenem Antibiotic
The FDA approved GSK and Spero Therapeutics’ Utebzi (tebipenem pivoxil) for adult complicated urinary tract infections. This oral antibiotic treats cUTIs and...